Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

Figure 1

Immunohistochemical evaluation of the presence and amounts of P-ERM and P-mTOR in MPM samples. Representative fields of epitheloid (A, C) and sarcomatous (B, D) tumor subtypes expressing P-mTOR (A, B) and P-ERM (C, D) are shown. P-mTOR is present in the cytoplasm of malignant mesothelia clusters. P-ERM are diffusely and uniformly expressed on the membrane of neoplastic mesothelial cells.

Back to article page